Gonorrhea

Evaxion Announces Business Update and Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, December 19, 2023
MSD, Partnership, Targets, Messenger, MTA, Biomarker, Research and development, WHO, Cancer, Vaccine, Gonorrhea, Merck & Co., Society, Research, AI, ASH, GHI, KOL, Merck, Patient, Infection, Development, Bone marrow, Melanoma, SITC, Pharmaceutical industry

On December 18, 2023, Evaxion priced a bridge financing round, expected to raise aggregate proceeds of approximately $5.3 million.

Key Points: 
  • On December 18, 2023, Evaxion priced a bridge financing round, expected to raise aggregate proceeds of approximately $5.3 million.
  • Cash burn for 2024, excluding financing activities, is expected at the level of $14 million (with Q1 cash burn being significantly higher than other quarters in 2024)
    COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provided a business update and announced its third quarter 2023 financial results.
  • A key focus for the first months has been to refine the Evaxion strategy with a strong focus on execution and value realization.
  • Evaxion announces a groundbreaking precision vaccine concept for hematological malignancies at the 65th American Society of Hematology (ASH) Annual Meeting.

Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea

Retrieved on: 
Monday, December 18, 2023
ASX, RCE, Risk, WHO, Ageing, Vaginitis, Mouse, Gonorrhea, Infection, Neisseria gonorrhoeae, Azithromycin, World Health Organization, Safety, Ceftriaxone, Vaccine

“The need for a new class of anti-infectives could not be greater, especially against a sometimes lethal pathogen, such as N. gonorrhoeae,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “The need for a new class of anti-infectives could not be greater, especially against a sometimes lethal pathogen, such as N. gonorrhoeae,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • After three days, the mice treated with R327 showed an approximate 4-log (99.99%) reduction in bacterial shedding, demonstrating significant bactericidal activity.
  • After five days of treatment, R327 showed a 3.5-log (>99.9%) reduction in bacterial shedding compared to the placebo-treated group.
  • A late-stage preclinical study comparing IV administration to a topical application of R327 against N. gonorrhoeae is underway.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

binx health Expands Nationwide Distribution of the binx io Molecular Point-of-Care Platform

Retrieved on: 
Monday, November 27, 2023
STI, Male, FDA, POC, Gonorrhea, Thermo Fisher Scientific, CLIA, World Congress, Chlamydia, Diagnosis, Female

BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced it has entered into a non-exclusive national distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the rollout of the CLIA-waived, FDA-cleared binx io, which will increase access to care and improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG).

Key Points: 
  • BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced it has entered into a non-exclusive national distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the rollout of the CLIA-waived, FDA-cleared binx io, which will increase access to care and improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG).
  • The binx io is the only molecular point-of-care (POC) platform proven to detect CT and NG in both male and female patient samples that provides central lab performance in about thirty minutes.
  • Data presented at the STI & HIV 2023 World Congress in Chicago demonstrated that hands-on-time for the POC binx io is statistically the same as the hands-on-time for collecting a CT/NG sample for send out to a central lab.
  • CT/NG results from the binx io were available days before test results were available from the central lab CT/NG test [1].

AHF Condom Ads Go Bananas in Miami

Retrieved on: 
Wednesday, December 13, 2023
Social Media, Healthcare Reform, Advertising, Pharmaceutical, Communications, Women, Infectious Diseases, Public Policy, Government, Men, Podcast, LGBTQ+, Biotechnology, Entertainment, AIDS, Consumer, Health, Behavior, STI, Jewish Healthcare Center (Worcester), Armenian American Wellness Center, AHF, Multimedia, Fruit, City, AIDS Healthcare Foundation, Pharmacy, Syphilis, Gonorrhea, HIV, Attitude, NW, Nightclub, Birth control, Closet

AIDS Healthcare Foundation ’s (AHF) “Just Use It” billboard campaign now is running in three new cities – Miami, Chicago, and New York City – after several national out-of-home advertising companies refused the artwork back in August.

Key Points: 
  • AIDS Healthcare Foundation ’s (AHF) “Just Use It” billboard campaign now is running in three new cities – Miami, Chicago, and New York City – after several national out-of-home advertising companies refused the artwork back in August.
  • This billboard in Miami is at NW 22nd Ave & NW 28th St (until 12/24/23).
  • It’s just a piece of fruit,” said Michael Weinstein, AHF president and cofounder.
  • “We may be moralistic in attitude, but the rising rates of STIs in Florida prove we are hedonistic in behavior.

AHF Condom Ad Goes Bananas in Chicago

Retrieved on: 
Tuesday, December 12, 2023
Lifestyle, LGBTQ+, Health, General Health, Women, Marketing, Advertising, Communications, Men, Infectious Diseases, Consumer, Behavior, STI, Jewish Healthcare Center (Worcester), Armenian American Wellness Center, AHF, Multimedia, Fruit, City, AIDS Healthcare Foundation, Pharmacy, Syphilis, Gonorrhea, HIV, Attitude, AIDS, Nightclub, Birth control, Franklin Street, Closet

AIDS Healthcare Foundation ’s (AHF) “Just Use It” billboard campaign now is running in three new cities – Chicago, New York City, and Miami – after several national out-of-home advertising companies refused the artwork back in August.

Key Points: 
  • AIDS Healthcare Foundation ’s (AHF) “Just Use It” billboard campaign now is running in three new cities – Chicago, New York City, and Miami – after several national out-of-home advertising companies refused the artwork back in August.
  • “It’s ridiculous we couldn’t run an ad with a condom-clad banana.
  • It’s just a piece of fruit,” said Michael Weinstein, AHF president and cofounder.
  • To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.

AHF Condom Ads Go Bananas in NYC

Retrieved on: 
Monday, December 11, 2023
Infectious Diseases, Advocacy Group Opinion, Marketing, Advertising, Communications, Public Policy, Government, AIDS, General Health, Health, Public Safety, Behavior, STI, Jewish Healthcare Center (Worcester), Armenian American Wellness Center, AHF, Multimedia, Fruit, City, Pharmacy, Syphilis, Gonorrhea, HIV, Attitude, AIDS Healthcare Foundation, Nightclub, Birth control, Closet

This board is at 575 Washington and W. Houston in NYC.

Key Points: 
  • This board is at 575 Washington and W. Houston in NYC.
  • It’s just a piece of fruit,” said Michael Weinstein, AHF president and cofounder.
  • “We may be moralistic in attitude, but the rising rates of STIs in New York prove we are hedonistic in behavior.
  • To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.

LetsGetChecked Receives U.S. Food and Drug Administration (FDA) De Novo Authorization for At-Home Chlamydia and Gonorrhea Testing System

Retrieved on: 
Thursday, November 16, 2023
Biotechnology, Medical Supplies, General Health, Health, FDA, Infectious Diseases, Health Technology, Other Health, Classification, Chlamydia, STI, De novo, Food, Gold, Doctor of Philosophy, Gonorrhea, HIV, CDC, Vertically transmitted infection, News, Medical device

LetsGetChecked, a global healthcare solutions company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo classification request for its Simple 2 at-home collection system.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo classification request for its Simple 2 at-home collection system.
  • FDA’s De Novo authorization makes LetsGetChecked’s testing system for chlamydia and gonorrhea the first-ever FDA-authorized home sample collection system with retail and online access to the collection kit.
  • The CDC reports that in 2021 there were an estimated 1.6 million cases of chlamydia and more than 700,000 cases of gonorrhea.
  • “We are honored to receive this landmark De Novo classification and authorization from FDA for our chlamydia and gonorrhea testing system, which demonstrates the value of our robust end-to-end at-home care system,” said Peter Foley, Founder and CEO of LetsGetChecked.

AHF Applauds Novel Gonorrhea Treatment

Retrieved on: 
Friday, November 3, 2023
AIDS, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Pharmaceutical, AIDS Healthcare Foundation, Disease, AHF, Clinical trial, Therapy, National Rural Development Partnership, Zoliflodacin, Lead, Gonorrhea, Infection, STI, Multimedia, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) applauds promising clinical trial results for a new drug zoliflodacin, which was co-developed by Swiss nonprofit Global Antibiotic Research & Development Partnership and U.S.-based company Innoviva Specialty Therapeutics to treat gonorrhea.

Key Points: 
  • AIDS Healthcare Foundation (AHF) applauds promising clinical trial results for a new drug zoliflodacin, which was co-developed by Swiss nonprofit Global Antibiotic Research & Development Partnership and U.S.-based company Innoviva Specialty Therapeutics to treat gonorrhea.
  • View the full release here: https://www.businesswire.com/news/home/20231103082562/en/
    The "Gonorrhea Alert" billboards, part of an ongoing outdoor advertisement campaign launched by AHF in the U.S., urges the public to visit the www.FreeSTDCheck.org website to learn more about the disease and find locations to access free testing and affordable care in the U.S. for the treatment of sexually transmitted infections.
  • It’s good to see a nonprofit taking the lead in developing a treatment in a space that has not seen significant innovation in many years,” said AHF President Michael Weinstein.
  • Among them is a series of billboards under the theme “ Gonorrhea Alert .”

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Wednesday, November 1, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Grand duchy, Food, Face, VWS, Disease, Gonorrhea, MHLW, Partnership, The Lancet, National Rural Development Partnership, Infection, Nursing care plan, Reproduction, SAMRC, Azithromycin, Hope, Physician, Prevalence, HIV, Ceftriaxone, BMBF, Neisseria gonorrhoeae, University, Therapy, Patient, Food and Drug Administration, Infertility, DFID, Heart, BMG, NIAID, MD, DHSC, AMR, BZ, Clinical trial, World Health Organization, Zoliflodacin, Woman, Multidrug-resistant bacteria, FOPH, South African Medical Research Council, Death, Ministry, Pharmaceutical industry, Vaccine, Medicine

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).